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Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in South Carolina and 
affects approximately 15 percent of the adult population. Unfortunately, recent data suggests that almost 
half of the COPD-affected population in South Carolina remains undiagnosed. Despite good evidence-
based guidelines for optimal care of COPD, the diagnosis, management, and outcomes for the disease 
are suboptimal and care is too often fragmented. Although tobacco cessation and avoidance are slowly 
advancing in South Carolina, 20 percent of COPD occurs in non-smokers, and this percentage will likely 
increase in the coming years. Therefore, a strategic plan must include other initiatives in addition to 
smoking cessation. 
COPD is a disease that reflects notable disparities in South Carolina: less  than 50 percent of COPD 
patients completed  high school, and African-American males are a group with relatively high rates of 
undiagnosed disease. Individuals who have COPD need a variety of services to optimize their care, 
including access to medications, durable medical equipment providers, pulmonary rehabilitation services, 
and knowledgeable health care providers who understand and screen for the co-morbidities frequently 
associated  
with COPD.      
This document was developed by a multidisciplinary group of health care providers, public health 
practitioners, and patients, as such a combined approach is imperative to target this disease. The SC 
Strategic COPD Plan was designed to advance the diagnosis and management of COPD in the state over 
the next five years and was done under the auspices of the National Heart, Lung, and Blood Institute 
(NHLBI)  “Learn More, Breathe Better” COPD awareness campaign. 
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Executive Summary 
Chronic obstructive pulmonary disease (COPD) is the third most frequent cause of death in the State of 
South Carolina. COPD has a tortured history in South Carolina: Tobacco was once an economic engine 
for the state. However, with cigarette smoking rates only slowly declining, COPD is projected to remain a 
costly cause of morbidity and mortality for the next three decades, with the majority of those costs affecting 
rural communities where tobacco was once king. Hidden within these statistics is the fact that at least 
20 percent of COPD is not caused by smoking. The next generation of non-smoking patients with COPD 
will be impacted by chronic inadequately treated asthma, childhood lung diseases that burden adult lung 
function, workplace exposure to fumes and occupational particulates, and more completely understood 
genetic susceptibility diseases. 
Today, COPD is common. The 2013 Center for Disease Control Behavioral Risk Factor and Surveillance 
Survey (BRFSS) included South Carolina COPD modules that recorded COPD prevalence at 9.1 percent 
for adults older than 35; 9.4 percent for adult women; 13.7 percent among those age 65 or older; and 25.6 
percent in adults over 45 years old with at least a 30-pack/year history of tobacco smoking (Liu, et al., 2015, 
Pleasants, et al. 2015). These rates are significantly higher than national averages. In addition, 8 percent 
of adults in South Carolina over age 35 have a cough, wheezing or dyspnea, have smoked for at least 10 
years are characterized as “high risk” for COPD. These individuals have never been tested for COPD and 
do not know that they have the disease. Under-diagnosis is common. 
COPD is costly. $1.9 billion is spent annually in direct health care costs caused by smoking tobacco 
products (Xu, et al., 2014). In 2014, there were 10,140 COPD-related hospitalizations and 41,546 COPD-
related emergency department admissions in South Carolina (SC RFAO, 2014). In 2014, $527 million was 
spent in COPD-related hospital and emergency department visitation costs (SC RFAO, 2014). These costs 
impact hospitals, municipalities, insurance premiums, households, and individuals with and without medical 
insurance. 
This document was prepared with a grant from the National Institute of Health “Learn More, Breath Better” 
Campaign. The grant, written by COPD experts from North Carolina who completed a similar process a few 
years ago, proposed to develop a strategic plan for COPD prevention, awareness, diagnosis, and treatment 
in South Carolina. The opportunity to learn from regional colleagues, foster shared programs on education 
and, most importantly, advance the care of South Carolina COPD to benefit patients with this burdensome 
disease was compelling. The document was assembled by volunteer efforts of a multidisciplinary team of 
people who touch patients with COPD in daily life. 
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As with any strategic plan, the goals always exceed current resources. However, we provide a vision to 
advance multidisciplinary care for a disease that requires multiple providers in a health care environment 
that is increasingly difficult to navigate for individuals with the worst diseases. Medication costs that 
contribute to non-compliance, inadequate use of current resources that can improve diagnostic and 
management outcomes, and over reliance on short-term solutions to chronic diseases are barriers to care 
that have evidence-based solutions. 
Specifically, the goals of the document are divided into sections on COPD prevention, awareness, 
diagnosis, management, and outcome assessments. Prevention is the most cost-effective solution. If 
strong laws are enacted to adequately resource proven strategies to limit cigarette access to youth and to 
increase efforts at smoking cessation in those who currently smoke, then COPD is lessened in incidence 
and severity. Separate prevention initiatives on vaccination are designed to lessen the incidence of acute 
exacerbations (flares) of COPD. The specific Prevention Objectives proposed are to:
1. Raise awareness among COPD patients and their health care providers of available tobacco 
cessation interventions (state and local resources).
2. Increase access to evidence-based tobacco cessation treatments and counseling for COPD patients.  
3. Support quality care initiatives concerning tobacco use screening and cessation, such as standards 
set by the U.S. Centers for Medicare and Medicaid Services (CMS) and The Joint Commission. 
4. Promote tobacco quit attempts and cessation through and by community-based organizations, 
workplaces, prisons, and existing health care programs, particularly those serving disparate 
persons, minorities, and other vulnerable populations.
5. Increase the percentage of pulmonologists and other health care providers who ask, advise and 
refer their COPD patients to evidence-based tobacco cessation treatment. 
6. Increase public awareness regarding the role of environmental tobacco smoke on children in the 
development and worsening of both COPD and asthma. 
7. Promote clean indoor and outdoor air quality in the environment.
8. Increase public awareness of the importance of receiving influenza , pneumococcal, and pertussis 
vaccinations in patients with lung diseases, including COPD.
9. Increase the vaccination rates in the COPD population for influenza, pneumococcal, and pertussis 
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based on published guidelines including the GOLD 
COPD guidelines and the CDC.
COPD is not a household word for a disease that is the 
third most common cause of mortality in South Carolina. 
Cough from cigarette smoking is often not recognized as 
the beginning of disease onset. Shortness of breath with 
exercise or carrying a load is often dismissed as part of 
normal aging. Wheezing is often seen in other diseases 
such as asthma and congestive heart failure. Therefore, 
awareness and COPD detection are intimately related 
topics. More specifically, awareness relates to a state of public recognition of this costly disease. Many 
of the implementation strategies to improve awareness will be public health advertisements that drive 
affected individuals to knowledgeable heath care practitioners. Knowledgeable health care practitioners 
will use spirometry, a test that assesses how well the lungs work, more frequently to accurately diagnose 
the disease and understand the nuances of COPD genetic risks, environmental causes, and clinical 
presentations. 
Therefore, the COPD Awareness Objectives are to:
1. Create a coalition to bring awareness of COPD to the general public in South Carolina.
2. Improve recognition in the primary care setting across the state.
3. Increase awareness of COPD symptoms and risk factors.
4. Understand the demographics of the COPD burden in South Carolina.
And the COPD Detection Objectives are to:
1. Expand the availability of spirometry.
2. Provide standardized spirometry and guidelines for the diagnosis and staging of COPD. 
3. Increase testing for Alpha-1 antitrypsin deficiency. 
Once a COPD diagnosis is established, the barriers to effective therapy in today’s health care systems add 
cost, time and ineffectual outcomes at many junctures. Evidence-based guidelines are available that are 
designed to treat the usual patient with COPD. Educational initiatives about those guidelines are limited. 
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There has never been better access to online literature directed at patients; however, the demographic 
affected by COPD includes disadvantaged populations that may not easily access this information 
or translate it into meaningful lifestyle lessons. Specific access to therapies that are proven to limit 
downstream costs and improve outcomes such as long-acting bronchodilators and pulmonary rehabilitation 
are subject to restrictive payer mandates that fail to account for other costs in the health care system. This 
is the longest section in the strategic plan to reflect where the most opportunities for improved care reside. 
Therefore, the COPD Management Objectives are to:
1. Promote patient and health care provider education of and adherence to guideline-based best 
practice treatment plans for COPD.
2. Educate providers and patients regarding different phenotypes of COPD.
3. Promote education for providers about the importance and availability of pulmonary rehabilitation 
programs in South Carolina.
4. Educate providers on clinical trials for the treatment of COPD.
5. Promote optimal pharmacotherapy prescribing, use and compliance to improve the well-being of 
patients with COPD.  
6. Identify and communicate community resources relevant for the care of COPD patients.
7. Communicate and encourage use of new evidence-based therapies.
The goal of improved health for all of South Carolina has led to significant consternation of how to reach 
historically disadvantaged populations in rural corridors of the state. Unfortunately, these are the same 
populations that have high cigarette sales, low educational performance, high prevalence of COPD and 
the highest risk of undiagnosed COPD populations. Some of the proposed solutions to these problems 
include telemedicine initiatives, improved education of rural health practitioners, and direct-to-patient 
initiatives in these communities. A further complication of COPD in these communities is that the patient 
with lung disease has an increased chance of having other co-morbid diseases such as heart disease or 
diabetes compared to the general age and smoking matched population. Therefore, these patients are 
more complex to manage because of their co-morbidities and need special care. The objectives advanced 
to deal with Special Populations in the COPD community are to:
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1. Further identify, define and decrease disparities in COPD prevention, diagnosis and management 
in South Carolina.
2. Improve awareness of significant COPD co-morbidities to include implications on prevention, 
diagnosis, and management of the disease.
3. Target persons with or at-risk for the asthma COPD overlap syndrome (ACOS) or COPD and 
obstructive sleep apnea to improve outcomes. 
COPD outcomes can be measured in many ways. However, uniformity in data collection, appropriate 
measurement of valid data with direct linkage to patient health, and frequent measurement are hallmarks 
of a program that can define if resources applied to this large health care problem are having desired 
effects. Administrative databases based on claims data are not generally regarded as accurate in this 
disease that has greater than 12 different codes for differing phenotypes of disease. Therefore, access 
to South Carolina specific data from national survey instruments is preferred and should be continually 
monitored as available. Therefore, the objectives to improve COPD Outcomes are to:
1. Use state and national health databases to help monitor disease prevalence and outcomes in 
S.C. adults with COPD.
2. Encourage use and communication of current quality improvement measures regarding COPD.
3. Increase utilization of strategies that can be used to measure and monitor clinical outcomes in 
COPD patients.
In summary, COPD will continue to be the third leading cause of death in South Carolina for many years. 
The costs associated with COPD are staggering and the disease impacts the economic, social and cultural 
fabric of the state. The status quo in which every patient with COPD is left to find their own resources 
and navigate a complex health care landscape costs the state immeasurably. For COPD, a disease that 
progresses for more than a decade on average before death, no care leads to higher costs of emergency 
room and hospital utilization, worse patient outcomes, and worse financial outcomes for the families 
affected. Furthermore, this is a disease of disparities in which those with less education and more rural 
sites of care have more disease and worse outcomes. 
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This strategic plan was generated by a cross-cultural and multidisciplinary group of individuals who hope 
that COPD care and prevention have a brighter future in South Carolina. They have all volunteered their 
time to share a vision in which South Carolina can be more healthy and prosperous. Unfortunately, the 
vision cannot be actualized without resources that target COPD prevention, detection and treatment 
strategies. Public funding, grants from federal, private and foundation sources, community resources, 
telemedicine initiatives, and donations of time, energy, and money from disease affected individuals are 
needed. 
The goals articulated in this strategic plan are necessarily broad and optimistic. However, the need for 
comprehensive health care reform to address severe chronic diseases like COPD has never been greater.  
Please help the State of South Carolina realize the vision of improved health regarding chronic lung disease.
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Perspectives from the COPD Patient Community
Jim Quill
I am from a family of five children who all have been diagnosed with 
COPD.  My oldest brother was the first to be diagnosed at age 38. 
Although a smoker, he was considered very young to be diagnosed with 
severe emphysema. In spite of many visits to several physicians, endless 
treatments and medications, his condition continued to rapidly decline. 
Finally, at age 44, he found a physician who tested him for a rare genetic 
disorder known as Alpha-1 Antitrypsin Deficiency or “Alpha-1”.  Alpha-1 is a 
genetic disorder that can cause liver disease in young children and liver/
lung disease at any age. Unfortunately, at the time of his diagnosis, there 
were no options for treating the genetic root of his lung disease. He was 
seeking a lung transplant when he was also diagnosed with liver disease. 
He passed away at the young age of 46. In addition to my oldest brother, 
other family members have succumbed to Alpha-10related lung/liver disease (mother, brother, sister, 
nephew). My brother’s Alpha-1 diagnosis provided our family with the critical education needed for us to 
seek physicians who know the condition, who test for the condition, and who know how to treat it.
In 1980, I was tested and diagnosed with Alpha-1 at age 29. Although asymptomatic for several years, I 
began to experience shortness of breath in 1988 and was diagnosed with COPD due to Alpha-1. In 1992, I 
was placed on augmentation therapy to slow the disease process, began to use supplemental oxygen, and 
participated in pulmonary rehabilitation programs, disease management through AlphaNet, Alpha-1 support 
group opportunities, and Alpha-1 Foundation-related events to do all I could to stay as well as possible. In 
spite of my efforts, my condition continued to slowly deteriorate. In 2000, I was placed on a lung transplant 
waiting list at the University of Pennsylvania, and after waiting several years with extremely poor lung 
health, I received a bilateral transplant on May 31, 2006. 
The transplant has provided me renewed health and a wonderful quality of life. However, it does present 
different challenges. I was unable to return to my career as an elementary school administrator due to the 
high risk of infection in that type of environment, and there is always the risk for rejection and other  
health-related issues due to the powerful transplant medications.
From my own personal experience as one who has Alpha-1, it is imperative that all those diagnosed with 
COPD be tested for this condition so that proper treatments, family testing and education can be accessed.
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Bill White  
I am a 55-year-old man with Stage 4 COPD and emphysema. My FEV1 is 16 
percent of normal. I was diagnosed with COPD in December of 2012, but 
continued to smoke. On May 31, 2014, I was admitted to the hospital with 
respiratory failure. 
I have had to retire due to this condition and focus on maintaining the best 
quality of life I can. The problems that faced me initially after my lengthy 
hospital stay were trying to seek out effective support and rehabilitation. 
I now attend Better Breathers, which is supported by the American Lung 
Association. I also participate in pulmonary rehabilitation three times per 
week and on off days, I go to the local gym. I truly feel that without the 
exercise, I would not be here.
Patients are ultimately responsible for seeking out their own education and support system. We must also 
recognize the high financial cost of COPD, from the drugs that can cost upwards of $300 per month to 
constant visits to the doctors.
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 EDITOR’S NOTE:  Julie–Marvin’s wife–is a caretaker for her husband. Having family and  
 friends’ support is immeasurable for those with COPD.
Marvin Sineath   
Having been an athlete all my life and giving up smoking shortly after 
returning from Vietnam, at the age of 23 I never considered the thought 
that I might have COPD. I continued working out and playing football, 
basketball, and tennis. When I reached my mid-30s I started experiencing 
shortness of breath during the spring. I went to my family doctor and he 
tried using allergy medications to correct the problem. Over time, things 
worsened and he thought that since I ran my own small business and 
invested in real estate, that it might be more of a stress- or heart-related 
problem. He sent me for a stress test year after year and I always passed 
them with flying colors. He never recommended a lung doctor because 
he knew of my athletic involvement and that I had quit smoking so long 
ago. I suggested that I see a pulmonary doctor. He referred me and I was 
diagnosed with Alpha-1 Anti-Trypsin Deficiency. I was shocked to find that I had emphysema and eventually 
was diagnosed with COPD. 
All this took about 10 years to figure out. I was diagnosed at age 46. Since that time, members of my 
family have been tested and are carriers of Alpha-1 or did not tell me the results. None of them show 
any symptoms except allergies. My Father died at age 49 in 1959 of cirrhosis of the liver and he did not 
consume alcoholic beverages; we now know it was because of Alpha-1.
COPD is a killer and a terrible disease to deal with, but you have to exercise and pray hard to help yourself 
to help the doctors help you. I am a 68-year-old white male and I am still fighting this horrible disease. I 
have not had a lung transplant.
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Perspectives from Health Care Providers
Physicians, nurses, nurse practitioners, physician’s 
assistants, pharmacists, physical therapists, occupational 
therapists, respiratory therapists, caseworkers and 
palliative care providers comprise a multidisciplinary 
team providing health care for persons with COPD. 
Knowledgeable providers should recognize, diagnose, 
educate, and treat patients with COPD. 
• Primary care providers, including family 
practitioners, internal medicine physicians, nurse 
practitioners, and physician’s assistants, diagnose and manage more than two-thirds of all COPD 
patients and are critical to management of the disease. Although spirometry access, performance 
and interpretation is sometimes challenging for primary care providers, especially in rural areas, 
spirometry is the only currently validated way to establish a diagnosis of COPD. 
• Pulmonary consultation should be considered in instances such as developing disease early 
in life, recurrent exacerbations or severe disease. Pulmonologists have advanced training and 
expertise in caring for patients with lung disease and will provide expert care, including diagnosis, 
management, and enrollment in clinical trials. The pulmonologist may provide an overarching care 
plan that can be overseen by the primary provider on a more frequent basis. 
• Respiratory therapists treat hospitalized COPD patients using a variety of medications and 
therapeutics aimed at improving airway clearance, reducing bronchoconstriction, and reducing 
airway inflammation. Therapists also help COPD patients requiring assisted ventilation or 
recovering from surgical treatment. In the outpatient setting, respiratory therapists may assist in 
the diagnosis and monitoring of disease progression with pulmonary function testing (PFTs) and 
assist with bronchoscopic evaluations. Also, respiratory therapists assist with formulation of patient 
care plans, providing home care therapeutics, and educating about medication use, breathing 
techniques, tobacco cessation and management of daily activities of living.
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• Pharmacists may work with patients in the community pharmacy, ambulatory care clinic, research, 
or hospital settings. Pharmacists dispense and provide counseling for medications, work with 
the patient, providers and insurance companies to coordinate affordable options, and assist 
with medication selection, and monitor drug therapies. Pharmacists may also promote tobacco 
cessation, optimize current drug therapies, provide inhaler teaching, and provide vaccinations.
• Occupational therapists can provide strategies that enable patients to carry out their daily activities 
and function at their highest possible level to improve quality of life. An occupational therapist will 
help the individual learn how to manage life’s activities by slowing their pace and alternating rest 
and activity. They also instruct patients on how to conserve energy so that they are able to engage 
in purposeful functional tasks and/or social activities and live more active, fulfilling lives. 
• Case managers assist the patient with coordinating care and facilitating transitions. They also 
connect patients with relevant resources in the community. These services may include, but are 
not limited to, referral to patient assistance programs providing low-cost drugs, housing and 
transportation options, and charitable organizations.
• Physical therapists design care plans that enable patients to reach and maintain their best 
physical condition. They may be part of the pulmonary rehabilitation team. Physical therapists use 
positioning, breathing exercises and therapeutic exercises as ways to help manage breathlessness 
associated with COPD. Physical therapists can also perform chest physical therapy to help clear 
patients’ lungs. The goal of physical therapy is to progress functional mobility and restore quality of life. 
• Palliative care providers may be engaged upon diagnosis to assist patients in achieving optimal 
quality of life while actively treating their COPD. Palliative care providers may also help patients 
and caregivers manage symptoms like pain and shortness of breath as well as proactively make 
decisions about end-of-life care and hospice care.
We welcome and encourage patients and families to be actively engaged partners  
in care.  
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Perspectives from the Public Health Community
The role of public health is to bring together resources 
that improve and impact the well-being of the state’s 
population. In South Carolina, legislated authority for 
public health rests with the Department of Health and 
Environmental Control (DHEC) whose mission is to promote 
and protect the health of the public and the environment. 
While many services at DHEC are regulatory in nature, 
other services are devoted to surveillance and tracking, 
prevention, intervention, and treatment of major chronic 
health conditions. Under the umbrella of Health Services, 
the Bureau of Community Health and Chronic Disease 
Prevention offers programs that focus on preventing and reducing the incidence and prevalence of major 
chronic diseases, while promoting protective and lifestyle interventions that help manage these conditions 
and reduce the burden of direct and indirect health care costs and lost productivity to our state. 
           
Early assessment of health problems and the implementation of evidence-based interventions are key 
drivers in public health practice. A comprehensive, multi-pronged public health approach is often needed 
when tackling the most serious chronic conditions; one that combines: (1) Prevention—proven efforts 
that reduce the likelihood of disease occurrence; (2) Policy—a set of guidelines, rules or procedures that 
are enacted to determine improved disease outcomes; and (3) Practice—systematic implementation of 
those evidence-based guidelines and protocols that are shown to help diagnose, treat and reduce the 
prevalence of disease.
           
Not enough is being done in South Carolina to address COPD from the public health perspective. As 
a progressive and costly disease, COPD greatly impacts the lives of individuals, families and entire 
communities. Successful public health interventions for COPD should include improving access to smoking 
cessation, protecting COPD patients from exposure to tobacco smoke and other environmental toxins or 
hazards in the home, workplace, or communities, and promoting preventive lifestyle interventions that can 
improve the quality of life for those living with COPD. Public health should also help educate the public 
about the disease.
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Burden and Impact of COPD in South Carolina
In 2000, an international survey on the impact of COPD in North America and Europe “confirmed the 
great burden to society and high individual morbidity associated with chronic obstructive pulmonary 
disease” (Rennard, 2002). Out of 201,921 randomly screened households, 3,265 self-reported that at 
least one occupant had COPD, chronic bronchitis, emphysema, or chronic respiratory symptoms, such as 
a productive cough or shortness of breath that limited physical activity. Over 35 percent of those under 
65 years of age reported previous years’ work loss directly related to COPD. Additionally, 12.8 percent 
were hospitalized, 13.8 percent reported an emergency department visit within the last 12 months, and 
61 percent reported taking medication due to COPD. Affected participants underestimated the severity 
of their disease, and COPD prevalence increased with decreasing socioeconomic status. Based on self-
reported data, diagnosed COPD prevalence was estimated at 6 percent within the general U.S. population 
(CDC, BRFSS, 2013).    
           
During the 2000 National Health and Nutrition Examination Survey (NHANES), 12.7 million Americans were 
diagnosed with COPD, and an additional 24 million showed evidence of pulmonary function impairment 
(ALA, 2013). National 2000-2010 COPD-related annual death rates were between 39.5 and 43.4 per 
100,000 for the standard U.S. population. If age-adjusted to those over 18 years of age, COPD-related 
annual death rates were between 43-46 deaths per 100,000 individuals (ALA, 2013). Non-Hispanic white 
males displayed the highest average age-adjusted death rate at 53 per 100,000 and “other” women (Asian, 
mixed race) the lowest at 11 per 100,000 (ALA, 2013).  
           
Chronic lower respiratory disease, primarily COPD, was the third leading cause of death in the United 
States in 2011 (Hoyert 2012), only marginally behind cancer and heart disease (ALA, 2013).   
For South Carolina:
• In 2013, COPD was the third leading cause of death in the state (CDC, MMWR, 2005).
• COPD prevalence was at 8.1 percent, compared with 6 percent nationally (CDC, BRFSS, 2013).
• COPD self-reported prevalence was highest among women at 9.4 percent (CDC, BRFSS, 2013).
• COPD prevalence was at 13.7 percent among those age 65 years or older (CDC, BRFSS, 2013).
• COPD prevalence was at 25.6 percent in adults over 45 years of age with at least a 30-pack/year 
history of tobacco smoking (Liu, et al., 2015).
• $1.9 billion is spent annually in direct health care costs caused by smoking tobacco  products  
(Xu, et al., 2014).
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• 28.3 percent of the COPD population are current smokers (CDC, BRFSS, 2013).
• In 2014, there were 10,140 COPD-related hospitalizations and 41,546 COPD-related emergency 
department admissions (SC RFAO, 2014).
• In 2014, $527 million was spent in COPD-related hospital and emergency department visitation 
costs (SC RFAO, 2014).
• COPD mortality is highest among non-Hispanic white males at 45 per 100,000 (ALA, 2013).
Also for South Carolina, those with COPD were:
• 3.97 times more likely to report “poor to fair” general health status,
• 2.2 times more likely to display physical activity limitations, and
• 2.1 times more likely to report 14 or more physically unhealthy days in the previous year when 
compared to South Carolinians without COPD (Antwi 2013).
Leading causes for COPD include tobacco smoke, environmental tobacco smoke (“secondhand”), 
occupational inhalation of dust, fumes, or chemicals, and indoor/outdoor air pollution (ALA, 2013). In the 
United States, 80 percent to 85 percent  of COPD incidence is directly associated with smoking or inhaling 
combustible tobacco. On average, 15 percent to 20 percent  of those diagnosed with COPD are never 
smokers (ALA, 2013). For those who smoke, the most important aspect of treatment is smoking cessation, 
while avoiding tobacco smoke and removing other air pollutants from a COPD patient’s home or workplace 
are also important. The Center for Disease Control’s (CDC) webpage on COPD prevention notes that, “In 
the United States, tobacco smoke is a key factor in the development and progression of COPD, although 
exposure to air pollutants in the home and workplace, genetic factors, and respiratory infections also play a 
role” (CDC, MMWR, 2005). 
As shown in the map, rural areas of South Carolina have relatively high rates of diagnosed COPD (SC 
BRFSS, 2012). This is consistent with smoking rates in those areas.
COPD is closely tied to smoking and, as seen with this map, retail sales of tobacco products are greater in 
areas of South Carolina that have high rates of COPD.
Clearly, COPD-related impact on health and the economy plays a detrimental role to the well-being of 
the residents of South Carolina. Therefore, a collective public health effort to reduce the burden of COPD 
throughout the state warrants immediate attention.
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Percent of Households Purchasing Seven Packs Plus of Cigarettes 
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Engaging Public Health Stakeholders
To combat COPD, prevention, policy and practice levels will require concerted and sustained efforts. COPD 
will improve in South Carolina only through collaboration, engagement and alignment of work across 
systems and organizations. While not an exhaustive list, there are certain key stakeholders who will need 
to be engaged in this work.
To address primary prevention, state government agencies, including DHEC, the Departments of Health 
and Human Services (DHHS), Alcohol and Other Drug Abuse Services (DAODAS), Mental Health (DMH), 
Social Services (DSS), and the State Department of Education (SDE), the three major research universities 
with public health components (Clemson, USC, MUSC), community-based organizations, the faith 
community, and major media outlets all will have an important role to play.
From a practice perspective, public and private South Carolina hospital and health care systems, along 
with the SC Hospital Association (SCHA), the SC Medical Association (SCMA), the SC Primary Health Care 
Association (SCPHCA), and other professional and technical associations that address COPD and related 
conditions are key stakeholders. In addition, entities responsible for training practitioners (such as schools 
of medicine, nursing, respiratory therapy and pharmacy) are integral to this work, as are organizations 
(public, private and nonprofit) that work to improve the practice of prevention and treatment related to 
COPD and other chronic conditions within the clinical setting. 
In the policy area, professional associations, state nonprofits [SC Tobacco Free Collaborative, the American 
Lung Association in SC, the SC Asthma Alliance (SCAA), and the Alliance for a Healthier South Carolina] will 
need to be engaged to advocate with policy makers for support of this plan.
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Perspective of the Pharmaceutical and Device Industries
The pharmaceutical industry has had a substantial impact 
on COPD through drug and device development. The 
industry also has had substantial influence by facilitating 
knowledge of medications and treatment of diseases as 
well as being advocates across the spectrum of health. 
Beginning more than 50 years ago with the development 
of the first metered dose inhaler, the pharmaceutical 
industry has developed more than 20 different drug 
therapies for COPD. Innovation has accelerated in the last 
five years with a number of new and investigational agents 
and devices, partially in response to increasing awareness 
of the burden of COPD and changes from the use of chlorofluorocarbons (CFC) as propellants in inhalers. 
As a consequence of drug therapies available today, COPD patients can have better control of respiratory 
symptoms, improved quality of life, fewer exacerbations and possibly better survival. 
The first widely used treatments for COPD in the United States were inhaled short-acting bronchodilators. 
Isoproterenol inhaler (Isuprel®), one of the few bronchodilators available in the 1970’s, had a short duration 
of action and caused excessive tremor and tachycardia. Safer short-acting bronchodilators, like albuterol, 
which is still heavily relied upon to relieve acute shortness of breath, were developed later. The next 
breakthrough in COPD medications was the availability of ipratropium, another inhaled bronchodilator that 
works by a different mechanism than albuterol. Together, the two provide additive bronchodilation—a key 
concept in the treatment of COPD. The subsequent development of long-acting bronchodilators, which 
work similarly to albuterol and ipratropium but are used only once or twice daily, provided a substantial 
improvement in treatment. In general, agents that require once- or twice-daily administration lead to better 
patient adherence than those required to be given more often, and are more convenient.  
Inhaled corticosteroids, principally used for their anti-inflammatory effects, were the next agents to 
gain widespread use in COPD; most often in a combination inhaler with a bronchodilator. Today, many 
patients with more advanced airway obstruction are receiving two long-acting bronchodilators and an 
inhaled steroid—called triple therapy. These agents may be augmented with oral drugs, such as low-
dose theophylline, which has been available since the 1950’s but its use is limited due to side effects 
and drug interactions. Roflumilast is a phosphodiesterase inhibitor biochemically similar to theophylline 
that is known to reduce exacerbations (flares) of COPD. A drug given by infusion, called Alpha-1 protease 
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inhibitor or Alpha-1 antitrypsin augmentation therapy, is also available for the treatment of Alpha-1 
antitrypsin deficiency, a genetic cause of emphysema. The potential benefit of other types of therapies, 
such as azithromycin and n-acetylcysteine, continues to be explored. In the future, agents that work 
on different cells and mediators that play an important role in the airways of the COPD patient may be 
available.  Medications that work similarly to corticosteroids, but with fewer side effects, could prove to be 
particularly impactful.
Another key area being addressed is the delivery of medications. “Smart Inhalers”–devices with counters 
to track doses and mechanisms that alert patients that a dose was appropriately taken–have already been 
developed and will be available soon. In addition, more efficient and user-friendly inhalers have or soon will 
become available, e.g.  “triple therapy” in a single inhaler. But the most common problem with inhalers is 
the patient not being able to afford them or being non compliant.
  
Cost is a major issue with COPD treatment; many commonly used medications are still only proprietary, 
and more than 50 percent of COPD patients have low annual incomes. Although the albuterol/ipratropium 
combination inhaler has been available for more than 25 years, it currently costs more than $200. Inhalers 
with long-acting medications often cost more than $300 for a one-month supply. Triple therapy along 
with an albuterol inhaler could cost a COPD patient nearly $800 per month without insurance subsidies. 
Medicare is the primary insurance for a substantial portion of the COPD population, and even those 
patients with prescription coverage often fall into the “doughnut hole” and may be unable to appropriately 
treat their COPD during these periods due to the costs. The pharmaceutical industry is required to help 
subsidize proprietary drugs for patients with Medicare Part D, but often the medicines are still unaffordable. 
Some elderly patients have to rely on the use of selected nebulized medications through Medicare Part B, 
but the available medications are limited.   
The complexity and cost of conducting studies needed to bring a generic inhaler to market are a barrier 
to development. The recent FDA-issued guidance on the development of generic inhaled agents such as 
ipratropium and availability of some of the products generically in 2017 will hopefully increase the number 
and types of inhalers available at a lower cost. There are no great solutions in the near future to target 
drug costs for the COPD patient. This is compounded by the drug costs necessary to treat other common 
comorbidities. Of note, some of these expensive medications decrease overall health care costs, largely 
due to decreasing COPD exacerbations (flares). Despite this, it is often difficult to engage policymakers 
and insurers about the financial benefits of secondary prevention with medications. Patient assistance 
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programs, which can be used to obtain some free or reduced-cost medications through pharmaceutical 
companies, are often very cumbersome and subsequently not readily used in most patient care settings. In 
South Carolina, WELLVISTA can provide reduced-cost or free medications for COPD patients who qualify 
(See Resources section). Proprietary drug samples provided by pharmaceutical industry, dispensed in some 
outpatient clinics by health care providers, are typically used to assess response to a new medication or 
to help patients get access to costly medications. The use of vouchers, rather than providing actual drug 
samples, is increasing, but Medicare patients are usually excluded, except for single-month supplies. 
Pharmaceutical industry and health care providers must work together to increase drug access and 
decrease drug costs to the COPD population. 
In addition to developing new agents for COPD, the pharmaceutical industry has also played a substantial 
role in the education of providers—such as the historic model in physician practices where sales 
representatives share key points about their products. New regulations and changes in pharmaceutical 
industry policies have led to a marked decrease in such interactions. The full impact of this decreased 
interaction is unknown. The pharmaceutical industry continues to support educational programs, 
albeit lower levels than in the past, for providers where experts share perspective at local and regional 
meetings. In health systems, pharmaceutical companies may provide outcome measurement tools, share 
best practices from other institutions, or find other ways to support the system in optimizing disease-
management programs.
Pharmaceutical companies are often interested in helping optimize disease-management programs in 
health systems. Examples include sharing best practices among different health care institutions and 
providing outcome measurement tools. Some have developed tools to assist providers in the care of 
individual COPD patients, such as COPD action plans and patient education materials. For both COPD and 
asthma, several companies have begun offering skilled personnel to train medical office staff to perform 
quality spirometry and to provide disease and drug education. In some instances, licensed pharmaceutical 
industry employees—such as respiratory therapists—assist in patient care.
The tremendous perspective across many areas of health and health care, whether it’s related to a specific 
medical practice, a major institution, or the government’s role in health care-related policies, is one of 
the greatest values of the pharmaceutical industry. Certainly pharmaceutical companies can function as 
health care organizations, not only to develop better and safer drugs and devices, but also by educating 
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and working with the public and health care providers to improve outcomes in the COPD population. 
The pharmaceutical industry, as a member of overall health care team, will continue to have a substantial 
impact on COPD through research, innovation, and facilitation.
The device industry has also been active in COPD. The understanding of drug particle size and mass 
that leaves a nebulizer device and where these particles deposit in the lung has led to more advanced 
nebulizer products. Since smaller drug particle sizes target the deep lung, these nebulizer devices become 
more efficient at drug delivery. The advantage of the inhaled route of drug delivery is that smaller drug 
doses can be given to optimize effects to the lung affected with COPD. 
For a selected group of COPD patients in which air enters the lung but becomes trapped in the enlarged 
airspaces of emphysema, new devices are in clinical trials to cause lung volume reduction. Lung volume 
reduction currently is performed surgically and has been shown to improve mortality for a subgroup 
of COPD patients. The new devices and procedures to effect a lung volume reduction using the 
bronchoscope are in late phase clinical trials in the United States, and have been approved in Europe. 
The bronchoscope is a lighted, flexible device that is steered into the lung to visualize the airways and 
allow site specific devices and procedures in the lung. Lung volume reduction with the bronchoscope has 
been performed with nitinol coils, one way valves and steam treatment of lung segments. The smaller 
resulting lung has less hyperinflation and improved respiratory mechanics. As a result, the patient has less 
shortness of breath and improved quality of life. 
The remainder of the strategic plan for COPD is presented with goal-directed 
recommendations to comprehensively improve prevention activities, awareness, 
diagnosis and management of COPD.
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COPD Prevention
PREVENTION GOAL 1 
Decrease the prevalence and impact of smoking tobacco 
products and other environmental exposures that lead to the 
development and/or worsening of COPD.
RATIONALE
More than 75 percent of COPD cases are due to prolonged use of combustible tobacco products, most 
often cigarettes. Occupational exposures, as well as secondhand smoke, are also known causes of COPD. 
Prevalence of tobacco use among adults in South Carolina is 17.8 percent (2012, SC Adult Tobacco Survey), 
which is consistent with the national average. A more recent telephone survey conducted by the Center 
for Disease Control placed adult smoking prevalence at 28.3 percent (2013 CDC BRFSS), higher than the 
national average. However, in the COPD population, prevalence of ever cigarette smoking is approximately 
double that of the general population at 40 percent. This is also true for asthma patients, many of whom 
will develop COPD with prolonged tobacco use. Health care providers play an integral role in helping 
patients quit tobacco, and evidence supports that advice from a physician leads to increased rates of 
smoking cessation. Additionally, research now supports the role of environmental tobacco smoke exposure 
in young children in increasing the risk of developing COPD later in life. (Johannessen 2013) Minimizing 
exposure to tobacco smoke and occupational irritants, and improving indoor and outdoor air quality are 
necessary steps to reducing morbidity and mortality in COPD patients. While smoking continues to slowly 
decrease, the number of nonsmokers developing COPD is rising. Thus it is important to focus on the role 
indoor and outdoor air quality play in the development of COPD. Air quality is also important for the well-
being of persons who already have disease. Short-term exposure to air pollution has been associated with 
exacerbation of COPD. New studies warn of serious effects from breathing ozone over longer periods. 
Encouraging “Healthy Home Assessment” is key for addressing obstructive lung diseases.   
OBJECTIVES 
1. Raise awareness among COPD patients and their health care providers of available tobacco 
cessation interventions (state and local resources).
2. Increase access to evidence-based tobacco cessation treatments and counseling for COPD patients.  
3. Support quality care initiatives concerning tobacco use screening and cessation, such as standards 
set by the U.S. Centers for Medicare and Medicaid Services (CMS) and The Joint Commission. 
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4. Promote tobacco quit attempts and cessation through and by community-based organizations, 
workplaces, prisons and existing health care programs, particularly those serving disparate 
persons, minorities and other vulnerable populations.
5. Increase the percentage of pulmonologists and other health care providers who ask, advise and 
refer their COPD patients to evidence-based tobacco cessation treatment. 
6. Increase public awareness regarding the role of environmental tobacco smoke on children in the 
development and worsening of both COPD and asthma. 
7. Promote clean indoor and outdoor air quality in the environment.
STRATEGIES
Objective 1—Raise awareness among COPD patients and their health care providers of 
available tobacco cessation interventions (state and local resources). 
1.1   Promote quit attempts through tobacco cessation awareness campaigns among the general public.
1.2  Identify and communicate best practices for smoking cessation interventions in health systems, 
medical practices and other settings, particularly those currently being used in South Carolina.
Objective 2—Increase access to evidence-based tobacco cessation treatments and counseling 
for COPD patients. 
2.1   Undertake educational interventions to promote state-of-the-art tobacco cessation interventions 
that align with the U.S. Public Health Service Clinical Practice Guideline, Treating Tobacco Use 
and Dependence: 2008 Update (Fiore  2008).  
2.2   Increase the number of certified tobacco treatment specialists in South Carolina by 
communicating available training programs. 
2.3   Engage community pharmacies to facilitate smoking cessation counseling and drug therapies 
through educational programs.
2.4   Increase insurance coverage for tobacco cessation treatments and counseling by engaging 
insurance companies and communicating to providers which companies provide such coverage.
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Objective 3—Support quality care initiatives concerning tobacco use screening and cessation, 
such as standards set by the Centers for Medicare and Medicaid Services (CMS) and The Joint 
Commission.
3.1   Engage the South Carolina Area Health Education Consortium system to provide more 
educational programs concerning tobacco use and tobacco-related diseases, including COPD.
3.2   Raise awareness among health care providers about tobacco use screening and cessation 
standards. 
Objective 4—Promote tobacco quit attempts and cessation through and by community-based 
organizations, workplaces, prisons and existing health care programs, particularly those 
serving disparate persons, minorities and other vulnerable populations.
4.1   Encourage system-wide smoking cessation programs that address tobacco use at all points of 
health care provision, including worksites and hospitals.  
Objective 5—Increase the percentage of pulmonologists and other health care providers who 
ask, advise and refer their COPD patients to evidence-based tobacco cessation treatment. 
5.1   Educate providers about the value of positive messaging for smokers.
5.2   Promote health care provider training in brief tobacco intervention through educational programs 
for health care providers, such as DHEC’s online CME training at www.helppatientsquitsc.org  
Objective 6—Increase public awareness regarding the role of environmental tobacco smoke 
on children in the development and worsening of both COPD and asthma. 
6.1   Undertake a public awareness campaign about the risks of combustible tobacco products 
(smoking cigarettes, cigars, etc.) and the use of electronic nicotine delivery systems [ENDS] 
(e-cigarettes and vaping devices) in asthmatics.
6.2   Promote messaging about children’s exposure to secondhand smoke in advertising, public 
service announcements and venues accessed by the general public.
6.3   Encourage children’s health care practitioners to counsel parents and caregivers about 
secondhand smoke exposure on an ongoing basis. Provide tip sheets and promotional materials, 
and include questions of secondhand smoke exposure on patient questionnaires.
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Objective 7—Promote clean indoor and outdoor air quality in the environment.
7.1   Promote awareness in the general population and COPD patients about the role of occupational 
exposures in the development and progression of COPD.
7.2   Promote advocacy for clean air policies that reduce environmental exposure to harmful airborne 
toxins, including indoor biomass fuels, such as use of wood stoves or open wood fires as a 
primary source of indoor heating, through engaging policy makers and the general public.
7.3   Increase the number of institutions, educational campuses, businesses, cities and counties with 
smoke-free ordinances and regulations. Promote policies to eliminate smoking and secondhand 
smoke exposure in workplaces and places open to the public.
7.4   Promote greater awareness of information sources on outdoor air quality, such as DHEC’s South 
Carolina Air Monitoring Network (http://gisweb01.dhec.sc.gov/monitoring/monitoring.html) and 
EnviroFlash (www.baaqmdsparetheair.enviroflash.info/signup.cfm?uCityID=28), an electronic 
information system designed to alert the public about air quality forecasts via email or the  
toll-free phone line at 1-866-238-4973.
7.5   Increase awareness of the Air Quality Index, especially among health care providers and patients 
with COPD. The Air Quality Index grades air quality exposure in terms of health effects. It is used 
as a tool to advise people to stay indoors when the pollution index is very high.
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PREVENTION GOAL 2
Optimize utilization of immunizations, specifically influenza, 
pneumococcal and pertussis in the COPD population and their 
household members as well as health care workers
RATIONALE
Vaccine protection is important in the management of COPD.  Progressed disability and death from COPD 
are greatly exacerbated by influenza and pneumonia. The National Heart Lung and Blood Institute (NHLBI) 
recommends that individuals with COPD should talk with their doctor about whether and when they 
should get flu (influenza) and pneumonia vaccines. These vaccines can lower the chances of getting these 
illnesses, which are major health risks for people who have COPD at any stage.
OBJECTIVES
1. Increase public awareness of the importance of receiving influenza, pneumococcal, and pertussis 
vaccinations in patients with lung diseases, including COPD.
2. Increase the vaccinations rates in the COPD population for influenza, pneumococcal, and 
pertussis based on published guidelines including the GOLD COPD guidelines and the CDC.
STRATEGIES
Objective 1—Increase public awareness of the importance of receiving influenza, 
pneumococcal and pertussis vaccinations in patients with COPD.
1.1   Promote utilization of the CDC Chronic Disease Indicator online database to access current rates 
of influenza and pneumococcal vaccinations in the COPD population in South Carolina.
1.2   Include the role of  vaccinations as an important preventive therapy for COPD to the general public 
and health care providers when addressing preventive therapies such as tobacco cessation.
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Objective 2—Increase vaccination rates in the COPD population for influenza, pneumococcal 
and pertussis based on published guidelines, including the GOLD COPD guidelines and the CDC.
2.1   Engage health care providers through education and sharing best practice models to achieve 
vaccination rates greater than 90 percent for all COPD patients as follows:  
a. Influenza vaccination annually including use of high-dose version in persons  
older than 65;
b. Pneumococcal vaccinations and boosters; and
c. Pertussis vaccination and booster.
2.2   Promote vaccinations in traditional and nontraditional settings to increase rates of use.
2.3   Distribute best practice models for vaccinations provided by the CDC.
2.4   Support CMS and other insurers’ guidelines for screening and administration of vaccinations in 
hospital settings.
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COPD Awareness
GOAL
Improve COPD recognition as a major public health issue and 
a common condition associated with significant morbidity and 
mortality. 
RATIONALE 
The most cost effective and patient-focused way to impact COPD is to prevent it. Of the many causes of 
COPD, tobacco use is the most common. Tobacco-related COPD is frequently viewed as a self-imposed 
condition and therefore may not get the same attention as other chronic diseases. Additionally, patients 
may deny symptoms as they develop because they do not want to admit that their actions have been 
injurious and/or that they do not want to change their lifestyle. Raising awareness and early detection are 
important strategies to identify patients prior to the development of symptoms or disability. As can be seen 
in the following figure, the prevalence of individuals who have smoked for more than 10 years and have 
pulmonary symptoms and also do not carry a current diagnosis of COPD is quite substantial, especially in 
the rural areas of South Carolina. 
Prevalence of At High Risk of COPD Among South Carolina
 Adults By Region 2012
Data Source: SC DHEC BRFSS
Map by: Division of Chronic Disease Epidemiology 6/2014
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Primary care providers deliver clinical care to about 60 percent of all COPD patients and are frequently 
engaged in the care of patients with undiagnosed COPD. A multi-faceted approach that involves public 
health agencies, health care professionals and health care organizations, including hospitals, clinics, 
pulmonary rehabilitation facilities, pharmacies and payers, is necessary to address these challenges. 
Awareness of COPD will require resources that become cost effective long term. Existing state resources 
that were established to address tobacco-related illness should be applied to COPD. Furthermore, public 
and private partnerships could find additional resources to target COPD awareness. These partnerships 
would optimally be directed by a broad base of health professionals with knowledge and interest in COPD.
OBJECTIVES
1. Create a coalition to bring awareness of COPD to the general public in South Carolina.
2. Improve recognition in the primary care setting across the state.
3. Increase awareness of COPD symptoms and risk factors.
4. Understand the demographics of the COPD burden in South Carolina.
STRATEGIES
Objective 1—Create a coalition to bring awareness of COPD to the general public in South 
Carolina.
1.1 Leverage public and private resources to establish a SC COPD Coalition. 
1.2 Develop a SC COPD Coalition to target the prevention, recognition, and management of COPD.
Objective 2—Improve recognition in the primary care setting across the state. 
2.1 Pursue grant funding for COPD education and awareness in various health care settings.
2.2 Change the stigma that COPD is a self-induced disease. 
2.3 Encourage use of questionnaires [e.g.COPD Population Screener(R) and Lung Function 
Questionnaire(R)]  and screening spirometry in primary care settings to identify undiagnosed 
COPD patients. The COPD diagnosis tools should be distributed to primary care providers and 
employer-funded wellness programs. 
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2.4 Utilize data from the 2012 SC BRFSS COPD At-risk Module to target persons in the general adult 
population who exhibit characteristics of those at high risk for undiagnosed COPD.  
2.5 Develop a network of trained respiratory care practitioners who can launch a statewide COPD 
community diagnosis program. 
2.6 Communicate the results of the diagnosis tools for patients to share with their primary care 
providers. 
2.7 Educate primary care providers regarding COPD guidelines established by the World Health 
Office (GOLD COPD), COPD Foundation, American Thoracic Society and American College of 
Chest Physicians
Objective 3—Increase awareness of COPD symptoms and risk factors.
3.1 Facilitate a public awareness campaign highlighting early signs and symptoms of COPD.
3.2 Educate the public and providers about the role of non-tobacco-related etiologies of COPD such 
as genetic causes and occupation and environmental exposures.
3.3 Target political action groups to assist in awareness efforts.
Objective 4—Understand the demographics of the COPD burden in South Carolina.
4.1 Utilize the SC BRFSS annual health survey and other health databases to define the prevalence 
and burden of COPD in South Carolina.
4.2 Increase collaboration among health care institutions and public health agencies to define and 
communicate the burden of COPD in South Carolina.
4.3 Communicate COPD epidemiology and health care utilization data to the public, health care 
providers, insurance organizations and policy makers.
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COPD Diagnosis
GOAL
Increase the number of persons at high risk for COPD or with 
a current diagnosis of COPD who have proper spirometry and 
clinical evaluation performed.
RATIONALE
COPD is nationally and internationally underdiagnosed and often is undetected until severely advanced. 
Some estimate that approximately half of the individuals with COPD remain underdiagnosed or 
misdiagnosed. COPD should be suspected in any individual 40 years or older with symptoms of cough, 
sputum production, or shortness of breath, and/or a history of exposure to risk factors, most notably tobacco. 
Technically, screening is a word applied to use of testing in asymptomatic populations. To date, the US 
Public Health Service has not recommended screening with spirometry to smoking individuals without any 
symptoms because the yield is low and outcomes are not different. However, the moment that respiratory 
symptoms occur, spirometry is not a screening test any longer. Spirometry is a test applied to understand 
the cause of symptoms. 
Simple spirometry is something that can be used in any health care provider’s office and can be used to 
quickly and easily determine if a patient has COPD. Spirometry is also used to stage the disease along 
with other parameters, such as shortness of breath, presence of exacerbations, exercise tolerance, and 
body mass. The Global Initiative for Obstructive Lung Disease (called the GOLD COPD guidelines) has 
created classifications that are internationally accepted and can be used to determine if patients have 
COPD. If present, COPD severity is also determined using spirometry. However the largest barrier to 
COPD detection is the lack of spirometric data to see if patients have obstructive disease. Although, use of 
questionnaires, peak flow meters and alternative forms of COPD detection are being explored, spirometry 
is the standard by which a COPD diagnosis should be established. Demographic features of populations at 
high risk for COPD are known. Spirometry applied to these populations with symptoms is evidence-based 
and improves care.
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Characteristics of Persons in SC At High-risk For Undiagnosed COPD 
(2012 SC BRFSS)
High-school or less education > college graduates
African Americans > Caucasians 
Males > females 
Current smokers > ex-smokers > never smokers
OBJECTIVES
1. Expand the availability of spirometry.
2. Provide standardized spirometry and guidelines for the diagnosis and staging of COPD. 
3. Increase testing for Alpha-1 Antitrypsin Deficiency. 
STRATEGIES
Objective 1—Expand the availability of spirometry.
1.1 Assess the availability of spirometry statewide, identify gaps in coverage and implement a plan 
to expand the pool of trained spirometry providers and equipment to areas lacking resources.
1.2 Develop a set of guidelines to be used for spirometry training and equipment maintenance. To 
ensure high-quality, reproducible results, spirometry testing providers will verify compliance with 
guidelines on an annual basis. 
1.3 Implement an electronic spirometry system, allowing trained professionals to complete the 
testing and electronically transmit the data to knowledgeable providers for expert interpretation. 
Objective 2—Standardize guidelines for diagnosis and staging
2.1 Establish an expert panel to develop consensus on diagnosis and staging guidelines and 
promote consistent use of the guidelines across the state. The diagnosis and staging guidelines 
will address airway disease severity (based on spirometry) as well as symptom severity. The 
guidelines will be reviewed and distributed to providers annually.
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Objective 3—Encourage primary care and lung specialists to screen for Alpha-1 Antitrypsin 
Deficiency according to published guidelines.
3.1 Identify practice models that incorporate Alpha-1 Antitrypsin Deficiency screening into routine  
patient care.
3.2 Communicate value of screening to health care providers considering that a drug therapy is 
available; identification of genetic carriers can improve genetic counseling of family members.
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COPD Management
GOAL
Ensure that SC COPD patients consistently have access to 
evidence-based state of the art treatment.
RATIONALE 
COPD is underdiagnosed and undertreated both at a state and national 
level. Therapeutic regimes require multidisciplinary providers who work most efficiently if patients are 
empowered in their care through education. Successful management of COPD must also incorporate 
community outreach interventions. Various clinical guidelines are available to guide management, but 
clinicians should individualize strategies for maximum patient response. 
South Carolina has a long way to go to improve COPD management. Care is often fragmented between 
health systems that do not communicate effectively between each other. Patient education is also 
fragmented and inadequately addresses optimal oxygen use, rescue and management plans, advance 
directives, and living with chronic lung disease. The most basic education of teaching patients such as 
how to properly use their inhaled medications is too often not done. Medication adherence is suboptimal 
with claims-based data suggesting that less than 50 percent of prescribed medications are filled at the 
pharmacy. 
Specific resources that limit overall costs but are poorly reimbursed are not being optimally used. 
Medications that decrease exacerbation frequency and costly emergency room and hospital stays are 
expensive at the patient care level, although improved compliance would save overall costs. Pulmonary 
rehabilitation improves COPD quality of life and hospital readmission rates, but access is too frequently 
limited due to costs and pragmatic issues such as transportation. There is no reimbursement for COPD 
education. The optimal goal that individuals become empowered in their care and lead healthier lives is not 
being realized because of system issues in the fragmented health care infrastructure of South Carolina. 
Although there are multiple evidence-based guidelines for COPD care, strict adherence to guidelines will 
marginalize the patient-specific variables that improve individual outcomes. Unique phenotypes of COPD 
require special care. COPD phenotypes who may require more resources include frequent exacerbators, 
those with concurrent asthma, and those with low body mass index, among others. Identifying the correct 
phenotype can allow for more individualized treatment and prognosis. Examples of a targeted approach for 
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specific phenotypes may include anti-inflammatory medications for chronic bronchitis, Alpha-1 Antitrypsin 
augmentation for hereditary COPD caused by deficiency of alpha-1 antitrypsin, and lung volume reduction 
interventions for severe emphysema with hyperinflation. 
Despite aggressive pharmacological interventions and lifestyle modifications (smoking cessation and 
pulmonary rehabilitation), patients continue to have poorly controlled dyspnea. Lung transplantation is 
used in select patients to extend their life and improve their quality of life. There are also potential new 
and emerging therapies that are in development for patients with advanced lung disease. Those include 
bronchoscopic volume reduction therapies with trials underway to have those interventions FDA approved.
OBJECTIVES
1. Promote patient and health care provider education of and adherence to guideline-based best 
practice treatment plans for COPD.
2. Educate providers and patients regarding different phenotypes of COPD.
3. Promote education for providers about the importance and availability of pulmonary rehabilitation 
programs in South Carolina.
4. Educate providers on  clinical trials for the treatment of COPD.
5. Promote optimal pharmacotherapy prescribing, use and compliance to improve the well-being of 
patients with COPD.  
6. Identify and communicate community resources relevant for the care of COPD patients.
7. Communicate and encourage use of new evidence-based therapies.
STRATEGIES
Objective 1—Promote patient and health care provider education of and adherence to 
guideline-based treatment plans for COPD.
1.1 Develop and conduct educational programs targeting primary care and allied health providers 
regarding current COPD guidelines.
1.2 Educate relevant students enrolled in health degree programs regarding COPD guidelines.
1.3 Establish an expert panel to develop a consensus of statewide best practice treatment 
guidelines and distribute to relevant health care providers and learners.
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1.4 Promote the use of individualized COPD Action Plans for each patient diagnosed with COPD.
1.5 Encourage health care providers to use staging of COPD severity that is based upon spirometry, 
frequency of exacerbations and frequency/severity of respiratory symptoms.
1.6 Identify common gaps between actual care and guideline-based care for COPD and 
communicate this data to health care providers.
1.7 Identify and communicate best practices for COPD in different settings.
1.8 Promote improved access to patient education materials to patients and health care providers. 
1.9 Promote local and regional educational programs to encourage better collaboration between 
primary care providers and specialists. 
1.10 Increase the use of health care providers to help COPD patients navigate available resources, 
especially when transitioning among multiple providers.
1.11 Help patients and families affected with COPD receive resources and education on the trajectory 
of the illness and prognosis of the disease.
1.12 Explore the potential for a state-specific website to provide patient and health care provider resources.                  
       
Objective 2—Increase provider and patient awareness regarding different phenotypes  
of COPD.
2.1 Educate health care providers and learners regarding COPD phenotypes, including the Asthma 
COPD overlap syndrome (ACOS), emphysema, chronic bronchitis and frequent exacerbator groups.
Objective 3—Promote education for providers about the importance and availability of 
pulmonary rehabilitation.
3.1 Educate health care providers on the importance of pulmonary rehabilitation and how it can 
improve the functional and mental status of COPD patients.
3.2 Encourage health care providers to refer patients to pulmonary rehabilitation throughout the state. 
3.3 Educate payers about the cost benefits of pulmonary rehabilitation services.
3.4 Connect pulmonary rehabilitation providers with a patient’s health care provider so individualized 
patient updates can be completed.  
3.5 Educate providers about a web-based map of pulmonary rehabilitation facilities in South Carolina 
to assist in patient referrals.
3.6 Improve patient education about COPD, therapies, and end of life discussions and assist with 
navigating the health care system. 
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Objective 4—Educate providers on results of key clinical trials for the treatment of COPD.
4.1 Identify and communicate web-based resources to providers and patients such as the American 
Association of Respiratory Care  RT web newsletter and US COPD Foundation monthly magazine 
(COPD Digest) that provide literature updates on COPD.
4.2 Expand live and web-based educational programs for SC health care providers regarding new 
drugs and devices for COPD.
Objective 5—Promote optimal pharmacotherapy prescribing, use and compliance to improve 
the well-being of patients with COPD.  
5.1 Educate health care providers to assess phenotype and pathophysiologic characteristics of 
patients with a new diagnosis of COPD and prescribe therapies using this information, and that 
individual response and disease progression may further impact medication selection.
5.2 Educate providers that initial therapy for COPD and exacerbations should be selected in 
accordance with guidelines for most patients.   
5.3 Disseminate guidelines and updated evidence to patients and providers through symposia or  
other means.
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5.4 Routinely employ algorithms and order sets to optimize treatment of COPD that includes 
checklists for vaccinations
5.5 Address tobacco cessation at each encounter with the offer of smoking cessation 
pharmacotherapy and referral to evidence-based community resources.  
5.6 Encourage patients to access clinical trial information if they qualify. 
5.7 Provide patients access to educational materials so they are informed about goals of therapy, 
medication options and available resources. 
5.8 Systematically evaluate each patient’s access to medications, medication use, and regimen 
appropriateness based on current symptoms and risk, co-morbidities, cost, and perceived value.
5.9 Patients with advanced or refractory disease should be treated by a provider well-versed in 
treatments that confer a benefit to selected patients, e.g., long-term azithromycin or roflumilast 
for exacerbation reduction.
5.10 Use advances in care delivery, including tele-health, to promote better communication between 
acute care facilities with expert providers and the community.   
5.11 Encourage health care providers, including community pharmacists, through education and, 
ideally, financial reimbursement to perform routine assessments of medication use.
5.12 Review treatment regimens upon initiation, every 72 hours, and upon discharge utilizing a 
multidisciplinary approach for hospital-based care.
5.13 Engage insurance companies to provide better access to medications with proven benefits in COPD.   
5.14 Increase collaboration amongst health care systems to improve access to results of testing, 
treatment plans and medication response. Explore options for reimbursement from payers for 
COPD Disease Management Programs. 
Objective 6—Identify and communicate community resources relevant for the care of COPD 
patients.
6.1 Establish a COPD Durable Medical Equipment Resource Group that will maintain a streamlined 
documentation, qualification and reimbursement guide for providers and patients. 
6.2 Maintain and share a list of human services and community resources specific to COPD 
populations for at minimum each DHEC region of the state. 
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6.3 Community Outreach—Align resources or obtain funding to ensure widespread availability and 
functionality of COPD-sensitive community resources in the categories below:  
a. Tobacco cessation counseling (including access to SC Tobacco Quitline)
b. Pharmacist support (including Medication Assistance Programs, Wellvista, etc.)
c. COPD-focused health fairs
d. Support organizations (including ALA’s Better Breathers, SC Society for Respiratory 
Care Patient Advocacy, Asthma Alliance)
e. Community Long Term Care resources (nursing assistants, care aides, etc.)
f. Transportation
g. Senior Services (through the Lieutenant Governor’s Office, including Meals on Wheels)
h. Obtain funding (grants or insurer reimbursement) to incorporate the use of 
telemedicine in the management of COPD (Potential telemedicine applications 
include virtual visits or consults with pulmonary specialists and/or pharmacists)
i. Virtual visits or consults with pulmonary specialists or pharmacists for patients with 
limited access (homebound or in rural communities)
j. Remote monitoring of symptoms, FEV1, cough and equipment compliance to prevent 
exacerbations via earlier interventions 
k. Use of mobile device applications for symptom management, medication 
management, nutrition and exercise goal setting, and progress tracking
l. Implementation of a Tele-health Pulmonary Rehabilitation Mode
Objective 7—Communicate and encourage use of emerging/future therapies. 
7.1 Educate providers on the utility of lung transplantation in patients with end stage COPD and 
what type of patients should be referred.
7.2 Promote use of a central site where providers can review potential COPD clinical trials so 
patients can be appropriately referred for new therapies.  
7.3 Utilize therapies with the main goal of reducing dyspnea and improve quality of life. 
7.4 Expand COPD management programs to decrease hospitalizations and emergency department visits.
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Special Populations with COPD
GOAL 
Improve recognition and health outcomes for special populations 
of COPD patients.
RATIONALE 
COPD is a complex pulmonary disease with many factors contributing to 
its development and progression. There are subtypes of patients within the COPD population that are 
particularly unique and warrant additional considerations–termed special populations.  
These include: 
• disparate populations at high risk for being diagnosed (low socioeconomic status, living in a  
rural area)
• at high-risk for undiagnosed disease (African American males)
• patients with certain concurrent chronic diseases/conditions (asthma, obstructive sleep apnea, 
extremes in body mass index)
• patients with multiple co-morbidities (multi-morbidities) 
• Alpha-1 Antitrypsin Deficiency.
Prevalence of COPD and household income are inversely correlated, largely due to substantially higher 
smoking rates, greater exposure to secondhand smoke often beginning early in life, occupational 
exposures, and higher rates of asthma that can lead to development of COPD. In South Carolina, the 
prevalence of COPD is four times higher in persons with less than a high school education (14 percent to 19 
percent) than the college graduates (3 percent to 5 percent). Persons with a high-school or less education 
account for more than 50 percent of all COPD patients, but less than 20 percent of the general population. 
These patients are often challenged to be able to afford delivery of health care, even with health insurance 
subsidies.
Gender and race are also important determinants regarding the risk of developing COPD, as well as long-
term outcomes. COPD has now become at least as prevalent in women as men. Women appear to be more 
likely affected by smoking tobacco than men. Race appears to influence mortality where the vast majority 
of COPD deaths in South Carolina are in Caucasian men and women; whereas in African Americans, other 
causes of tobacco-related diseases are more likely to be the principal cause of death (such as lung cancer). 
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A disparity in South Carolina related to race and gender appears among African American males. According 
to the 2012 SC BRFSS, this group makes up a disproportionate number of persons who are at high risk for 
undiagnosed COPD. 
A diagnosis of COPD increases the number of co-morbidities, compared to the general population. 
Although co-morbidities are common in COPD due to the advanced age and suboptimal health behaviors 
such as smoking and nutrition, in this population, good data suggests that the presence of lung disease 
adds to the risk for these other diseases. The result is that more than 80 percent of patients with COPD 
have additional health conditions that complicate management. Some key co-morbidities in COPD include: 
• Heart disease (both coronary artery disease and congestive heart failure)
• Arthritis
• Diabetes
• Obesity
• Depression
In South Carolina, more than one-third of COPD patients also report having asthma. This condition, known 
as asthma-COPD overlap syndrome, may in part be due to underdiagnosis of wheezing and dyspnea 
as COPD. However, good data suggests that this phenotype of COPD with prominent bronchodilator 
responsive symptoms has much worse outcomes than COPD without bronchodilator symptom reversibility. 
These patients often have more severe disease than either asthma or COPD alone and are frequent users 
of health care. Similarly, another co-morbidity, obstructive sleep apnea (OSA), is often present in COPD and 
if untreated is a substantial factor leading to worse outcomes. This is sometimes referred to as the COPD 
and OSA overlap syndrome. Lastly, many COPD patients have multiple chronic illnesses; if three or more 
co-morbidities are present, the term multi-morbidities is used. More than one-half of COPD patients have 
multi-morbidities and patients’ health status if often worse and care is complex.
Among the 12,500 diagnosed COPD patients in South Carolina, there are those who have a genetic 
cause for their lung disease. Alpha-1 antitrypsin deficiency, or Alpha-1, is a genetic disorder that can cause 
lung disease in adults and lung/liver disease at any age. It is present in about 3 percent of diagnosed 
COPD cases. The Medical University of South Carolina is nationally-recognized in the investigation and 
management of this type of COPD. Early identification of this disease is key for the patient in order to 
receive optimal management as well as identify family members who are at risk, especially siblings, 
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children and grandchildren, in order to provide counseling on genetics and minimizing risk factors such as 
smoking and occupation. (See Patient Perspectives) 
OBJECTIVES
1. Further identify, define and decrease disparities in COPD prevention, diagnosis and management 
in South Carolina.
2. Improve awareness of significant COPD co-morbidities to include implications on prevention, 
diagnosis, and management of the disease.
3. Target persons with or at risk for the asthma COPD overlap syndrome (ACOS) or COPD and 
obstructive sleep apnea combination to improve outcomes 
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STRATEGIES
Objective 1—Further identify, define and decrease disparities in COPD prevention, diagnosis 
and management in South Carolina.
1.1 Provide more comprehensive education for health care providers about the existence of 
disparities within COPD patient and at-risk populations.
1.2 Ensure health care providers are trained on how to collect and use race and ethnicity data 
as well as social determinants of health assessments to support population health efforts in 
communities.
1.3 Organize resources to allow for better education of the general public and at-risk groups about 
disparities in COPD populations.
1.4 Engage health care, human and social service providers in directing resources to COPD patients 
with high socio-economic needs.
1.5 Promote linkages to COPD management strategies that impact rural areas specifically  
(e.g. patient navigation and telemedicine).
Objective 2—Improve awareness of significant COPD co-morbidities to include implications on 
prevention, diagnosis and management of the disease.
2.1 Increase awareness among health care providers of the role of key co-morbidities in the COPD 
patient population, including the common conditions of heart disease, lung cancer, arthritis, 
diabetes, obesity, depression and obstructive sleep apnea syndrome.
2.2 Provide screening questionnaires to aid clinicians and patients in the recognition of depression.
2.3 Promote CMS guidelines for use of low-dose CT scans for lung cancer screening.
Objective 3—Target persons with or at risk for the asthma COPD overlap syndrome (ACOS) or 
COPD and obstructive sleep apnea overlap syndrome to improve outcomes.
3.1 Promote awareness and management strategies for asthma COPD overlap syndrome using 
published ACOS guidelines.
3.2 Increase awareness of COPD and obstructive sleep apnea overlap syndrome through health 
care provider education and provision of screening questionnaires to identify high-risk persons 
(e.g. STOPBang questionnaire).
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COPD Outcomes
GOAL
Define, communicate and promote the use of appropriate 
outcomes measures for the prevention, recognition and 
management of COPD in South Carolina.
RATIONALE
Outcomes measures for COPD include those for the individual patient, the health care provider, and health 
care organization as well as those at the public health level. Patient-centered outcomes are symptom- 
based outcomes that result when patients and health care providers collaborate in informed health care 
decisions. The ability to accomplish usual daily activities and having a good overall health status are some 
important patient-centered measures. These can be measured through various tools. 
At the patient-doctor level, symptom-based questionnaires are available for COPD to assess outcomes and 
include the COPD Assessment Test (CAT) and modified Medical Research Council dyspnea scale (mMRC). 
These particular questionnaires also help to define the stage of disease severity as well as to monitor 
progress of the patient, they are recommended for use by the GOLD COPD Guidelines and are therefore 
important tools to measure outcomes in individual patients. Evidence indicates that symptom-based and 
other types of questionnaires should be used more often with patients in the domiciliary and institutional 
settings. 
The National Institutes of Health recently defined biomarkers (Mannino 2015)  as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention.” Historically, the breathing test value FEV1 has 
been used as a principal measure (biomarker) to predict outcomes, stage disease severity and assess 
response to investigational drugs.  
A COPD Foundation Biomarker Consortium has worked in this area and in 2015, the Food and Drug 
Administration adopted the use of fibrinogen in the blood as an additional surrogate marker for outcomes 
in COPD.  
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Quality care initiatives by major national health agencies now necessitate measurement of certain 
outcomes by health care providers, whether at the practice or institutional level. These include:
• The Health care Effectiveness Data and Information Set (HEDIS) by NCQA is a package of quality 
improvement measures regarding appropriate diagnosis and management of exacerbations. 
• The Committee on Medicare and Medicaid Services (CMS) rules about tobacco interventions in all 
patients and 30-day hospital readmissions in certain conditions, including COPD.
Combined, these measures can affect the COPD patient at different points in their transitions across health 
care. As a consequence of the CMS regulations, this has led many hospitals to implement transition of care 
models and medical home strategies for COPD. Finally, all health care settings are now required to screen 
and document  tobacco use and in certain instances, such as during hospitalization, are required to provide 
smoking cessation counseling. This is key for the prevention of COPD as well as dealing with high current 
smoking rates in COPD patients.
The CDC, state and local health agencies work to collect, disseminate, and monitor many diseases, 
including COPD. The CDC works with states to conduct large health surveys each year and currently one 
of the principal sources of COPD epidemiology is the Behavioral Risk Factor Surveillance System (BRFSS) 
health survey. The BRFSS is conducted each year in South Carolina in more than 10,000 adults and 
provides prevalence of numerous chronic diseases as well as sociodemographic and health characteristics. 
The SC BRFSS annual survey currently includes a COPD prevalence question and is described in the 
Awareness Section. 
The CDC recently updated chronic disease indicators for COPD. These indicators are used by state and 
local health departments to help monitor outcomes of COPD in the United States. 
These include:
• COPD prevalence 
• proper immunizations 
• emergency department visits (COPD as primary or secondary diagnosis)
• hospitalizations for COPD exacerbations (COPD as primary or secondary diagnosis)
• mortality  (COPD as primary or secondary diagnosis)
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OBJECTIVES
1. Use state and national health databases to help monitor disease prevalence and outcomes in 
South Carolina adults with COPD.
2. Encourage use and communication of current quality improvement measures regarding COPD.
3. Increase utilization of strategies that can be used to measure and monitor clinical outcomes in 
COPD patients.
STRATEGIES
Objective 1—Use state and national health databases to help monitor disease prevalence and 
outcomes in South Carolina adults with COPD. 
1.1 Use and report COPD outcome measures reported by the CDC’s Chronic Disease Indicators, 
including mortality, hospitalizations, immunizations and prevalence in South Carolina.
1.2 Continue to use the annual SC BRFSS health survey to monitor the prevalence and 
characteristics of adults who report COPD.
Objective 2—Encourage use and communication of current quality improvement measures 
regarding COPD.
2.1 Increase health care providers’ and other’s awareness of quality improvement measures by 
regulatory organizations, including those by CMS, The Joint Commission and HEDIS.
Objective 3—Increase utilization of strategies that can be used to measure and monitor clinical 
outcomes in COPD patients.
3.1 Educate clinicians and provide resources to them regarding the use of disease staging and 
monitoring tools consistent with current GOLD Guidelines.
3.2 Include use of existing and new COPD biomarkers in educational programs to health care 
providers.
3.3 Incorporate COPD questions in Community Health Needs Assessment Surveys to help monitor 
and report the impact and prevalence of COPD at health care institutions in South Carolina.
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Resources
General Smoking Cessation 
Resources in South Carolina 
Statewide, Population-Based Quitline:
South Carolina Tobacco Quitline 
Patients can contact the Quitline for free help 
to quit or a fax or eReferral from a provider will 
prompt the Quitline to contact the smoker.
1-800-QUIT-NOW
www.scdhec.gov/quitforkeeps/
HelpYourPatientsQuit/  
Hospital-Based Smoking Cessation Programs:
SC Hospital Map
www.scdhec.gov/tobacco/TobaccoQuitline/
OtherHelpfulTools/
Other Smoking Cessation resources:
http://smokefree.gov/apps
You Quit Two Quit
For pregnant and postpartum women, mothers 
and families.
www.youquittwoquit.com
Community-Based Smoking Cessation Programs:
American Cancer Society
www.acsworkplacesolutions.com/quittobacco.asp
American Lung Association 
www.lung.org/stop-smoking
Freedom From Smoking®
The program is offered as an in-person group 
clinic, an online program available at  
www.FFSonline.org and a self-help manual. 
Typically offered in the community by a trained 
FFS facilitator.
Freshstart®
A group-based tobacco cessation support 
program offered by the American Cancer Society 
that is geared to help participants increase their 
motivation to quit, learn effective approaches for 
quitting and guide them in making a successful 
quit attempt. Typically offered at worksites by a 
trained Freshstart facilitator.   
www.acsworkplacesolutions.com/freshstart.asp
South Carolina COPD Strategic Plan 41
COPD Resources For Patients  
and Health Care Providers in  
South Carolina*
Alphanet
A not-for-profit organization that offers support, 
education and advocacy for individuals with 
Alpha-1 Antitrypsin Deficiency. 
www.alphanet.org
Alpha-1 Foundation
A not-for-profit organization with several programs 
that spread awareness and education for 
individuals with COPD, including Alpha-1 Clinical 
Resource Centers (CRC), the Alpha-1 Research 
Registry, other research programs and information 
on Alpha-1. www.alpha1.org
American Academy of Family Physicians  
Health and drug information. www.aafp.org
American College of Chest Physicians 
Resources for health care providers and patients, 
including an extensive manual for COPD patients. 
www.chestnet.org
American Lung Association of the Southeast
Here you can find a local ALA chapter in NC, 
SC or GA, flu clinic locator, help with treatment 
decisions for COPD and definitions for lung 
diseases. www.lung.org
American Thoracic Society
Patient and health care professional education 
on COPD. Including ATS/ERS Standards for the 
Diagnosis and Management of Patients with 
COPD. www.thoracic.org
COPD-Alert Support and Advocacy Group 
Frontline Advice for COPD Patients, information 
on COPD and the NHLBI Learn More Breathe 
Better COPD Awareness Campaign.
www.copd-alert.com
The COPD Foundation
This patient-friendly site provides COPD detection 
tools, a 360 Social Media Chatroom, and a wealth 
of COPD educational tools through the BFRG 
(the Big Fat Reference Guide). The COPD patient 
powered research network (PPRN) registry is 
housed here and individuals with COPD are 
encouraged to sign in and generate a password 
to access the full materials. 
www.copdfoundation.org
COPD-International
COPD chat rooms, information, library for medical 
information and support for caregivers.  
www.copd-international.com
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Emphysema Foundation For Our Right  
To Survive
Information and support for people with 
emphysema and COPD.  
www.emphysema.net 
The Global Initiative for Chronic Obstructive 
Lung Disease
Works with health care professionals and public 
health officials around the world to raise COPD 
awareness and to improve prevention and 
treatment of this lung disease. Through the 
development of evidence-based guidelines for 
COPD management, and events such as the 
annual celebration of World COPD Day.  
www.goldcopd.org
Learn More Breathe Better® COPD Campaign 
Public awareness campaign of NHLBI that 
facilitates COPD events and other activities across 
the United States. www.nhlbi.nih.gov/health/
educational/COPD/LMBB-Campaign
Medline Plus  
A service of the U.S. National Library of Medicine 
and the National Institutes of Health. Contains a 
medical encyclopedia, dictionary and information 
to help answer health questions.
www.nlm.nih.gov/medlineplus
Medscape 
Wed-based resource for diseases and treatments 
for patients and health care providers. 
www.medscape.com/pulmonarymedicine
National Heart, Lung, and Blood Institute 
Information and research related to the causes, 
prevention, diagnosis, and treatment of heart, 
blood vessel, lung and blood diseases, and 
sleep disorders for patients, the public, health 
professionals, and researchers. www.nhlbi.nih.gov
National Lung Health Education Program 
Contains several resources for patients and health 
care professionals on COPD. www.nlhep.org
Partnership for Prescription Assistance  
Helps identify resources and clinics where low-
cost or free medications may be available.
www.pparx.org/prescription_assistance_
programs/free_clinic_finder
Pulmonary Rehabilitation Programs in SC   
www.cardiorehab.weebly.com/south-carolina
SC Asthma Alliance  
State based asthma alliance
www.scasthmaalliance.org  
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US COPD Coalition
The U.S. COPD Coalition (USCC) consists of 
patient organizations, health professional 
organizations, individuals and government 
agencies who promote the interests of individuals 
affected by COPD. www.uscopdcoalition.org
Welvista
Non-profit organization that assists with providing 
medications to the uninsured or underinsured in 
North Carolina. Has some medications available 
for the treatment of COPD.  Targets persons less 
than 65 years old who do not have other forms of 
insurance with a household income less than 200 
percent of the poverty level. www.welvista.org 
 
*Links can be accessed through electronic 
versions of this document
The COPD Foundation graciously provided many 
of the list/links. See more at: 
www.copdfoundation.org/Learn-More/Other-Links/
Organizations-Resources.aspx#sthash.DeKeMqo4.
dpuf
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Summary and Future Directions
COPD will continue to be the third leading cause of death in South Carolina for many years. The costs 
associated with COPD are staggering and the disease impacts the economic, social and cultural fabric 
of the state in impactful ways. The status quo in which every patient with COPD is left to find their own 
resources and navigate a complex health care landscape costs the state immeasurably. For some 
diseases, no care is the cheapest care. For COPD, a disease that progresses for more than a decade on 
average before death, no care leads to higher costs of emergency room and hospital utilization, worse 
patient outcomes and worse financial outcomes for the families affected. Furthermore, this is a disease of 
disparities in which those with less education and more rural sites of care have more disease and worse 
outcomes. 
This strategic plan was generated by a cross-cultural and multidisciplinary group of individuals who hope 
that COPD has a brighter future in South Carolina. They have all volunteered their time to contribute to this 
document to share a vision in which South Carolina can be healthier and more prosperous. 
Unfortunately, the vision cannot be actualized without resources that target COPD prevention, detection 
and treatment strategies. Implementation of any strategic plan is always more difficult than writing about 
what needs to be done. Public monies, grants from federal, private and foundation sources, community 
resources, telemedicine initiatives, and donations of time, energy and money from disease affected 
individuals are needed. 
Therefore, what becomes most important as the next step from this document is an engaged leadership 
plan that might emerge from some of the members of this writing committee. The strategic plan calls for 
formation of a South Carolina COPD Coalition. What form this coalition takes will determine chartering 
characteristics and governance, funding and mission. New organizations often die a slow death when 
a mission is not adequately funded or a project is not sufficiently concrete. The goals elaborated in this 
strategic plan are necessarily broad and optimistic. However, the need for comprehensive health care 
reform to address severe chronic diseases like COPD has never been greater. Please help the state of 
South Carolina realize the vision of improved health regarding chronic lung disease.
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